Navigation Links
Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit

WHITE PLAINS, N.Y., AUG. 2 /PRNewswire-USNewswire/ -- Two major studies published today in The New England Journal of Medicine can help doctors better identify pregnant women at risk for preterm delivery who can benefit from progesterone treatment, the March of Dimes Foundation said today.

In one large multi-center trial led by Eduardo B. Fonseca, M.D., women with short cervix (most of whom had no prior history of preterm birth) who received progesterone suppository treatment between 24 and 34 weeks gestation had a greatly reduced rate of preterm birth.

Another large multi-center trial led by Dwight J. Rouse, M.D., found that weekly injections of 17P (17 alpha-hydroxyprogesterone caproate, a derivative of progesterone) between 16 and 35 weeks gestation did not reduce the rate of preterm birth among women carrying twins.

"Premature birth is a growing problem in the United States and a leading killer of newborns," said Michael Katz, senior vice president for Research and Global Programs of the March of Dimes. "With this new information, physicians will have a better idea of how to identify those women who are most likely to benefit from progesterone treatment from those who are not."

Dr. Katz noted that pathways to preterm birth may differ substantially between singleton and twin gestations. For example, progesterone may be more effective against some pathway that does not involve the uterine over- distention seen in twin pregnancy.

"We need more research into the underlying causes of prematurity to help women with other risk factors," Dr. Katz said.

In previous studies (Meis et al., NEJM, 2003;348:2379-85; da Fonseca et al., Am J Ob Gyny, 2003;188:419-24), the benefit of progesterone was seen in women with singleton pregnancies and a documented history of a previous spontaneous preterm birth. These study results led to a Committee Opinion issued by the American College of Obstetricians and Gynecologists on the use of progesterone therapy, published in the October 2003 issue of Obstetrics & Gynecology.

The March of Dimes works to improve the health of babies by preventing birth defects, premature birth and infant mortality. For more information, visit or for Spanish language information.

SOURCE March of Dimes Foundation

Copyright©2007 PR Newswire.

Related medicine technology :

1. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
2. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
7. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
8. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
9. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
10. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
11. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015 ... today announced that its Chief Executive Officer, ... the Oppenheimer Annual Healthcare Conference in New ... in the conference through a webcast on ... , --> ...
(Date:12/1/2015)... India and PITTSBURGH , ... today announced that it expects to be the first ... markets funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate ... mg) for $99 per patient, per year. Mylan partnered ... TLE400. The significantly reduced price could generate savings of ...
(Date:12/1/2015)... Breg, Inc ., a premier provider ... it has been awarded three contracts by Novation, a ... will have access to improved pricing for Breg,s portfolio ... goods dedicated to advancing orthopedic care.  ... population, rising prevalence of chronic conditions and the health ...
Breaking Medicine Technology:
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
(Date:12/1/2015)... ... December 01, 2015 , ... The workstation boundaries for imaging ... Information Systems launches MED-TAB™ -- the world’s first portable DICOM-calibrated medical image display, ... to December 4, 2015. , MED-TAB is expected to change teleradiology because ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken at ... accurate interpretation by the radiologist. The marking utensils are so small, however, they ... found a way to alleviate this problem. , He developed the patent-pending MARK ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... of Excellence (BHCOE) today announced that the organization has awarded Education and Developmental ... with a Distinguished Award. The award celebrates exceptional special needs providers that excel ...
(Date:12/1/2015)... ... 2015 , ... Lutronic, a leading innovator of aesthetic and medical laser and ... for sale in the United States. Clarity is a Superior Dual Wavelength Platform ... into a single platform that is easy to own and operate. , For ...
Breaking Medicine News(10 mins):